Should I buy NOV Inc. (NOV) stock or is it too late?
⭐ The most reliable of them, either direction: Susquehanna — 58% of its targets hit on this sector (31 calls tested). It aims for $24 (+16 %), call made on July 31, 2026, maturing on July 31, 2027 (28 d ago).
Firm-by-firm track record on NOV Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 60 % | +30.9 % | 5 | $23 +11% |
| Susquehanna | 50 % | +13.8 % | 6 | $24 +16% |
| Citigroup | 71 % | +5.6 % | 7 | $22 +6% |
| Morgan Stanley | 38 % | +3.4 % | 8 | $20 -4% |
| Barclays | 40 % | -13.8 % | 5 | $20 -4% |
| Wells Fargo | 60 % | -20.3 % | 5 | $10 -52% |
| Goldman Sachs | 20 % | -25.0 % | 5 | $20 -4% |
| Raymond James | 60 % | -1.5 % | 5 | — |
✅ Reasons to believe
- The most reliable firm on NOV, RBC Capital (100% hit rate, 3 scored calls), targets $22 (call made on April 29, 2026, maturing on April 29, 2027) (+6%) in its most recent call, and $19 (call made on October 29, 2025, maturing on October 29, 2026) (-8%) in the one coming due soonest.
- Pays a dividend (2.7% yield) — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 9 ratings, 4 are neutral and 2 are sells.
- Limited upside: the median target is only +6% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Volatile stock: sharp swings — including steep drops — are part of its profile.
The analyst consensus on NOV
Median target $22 (+6%) · 9 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in NOV Inc. now?
We won't decide for you. The facts: 33% of analysts rate it a buy, median target $22 (+6%), and RBC Capital (most reliable on NOV, 100%) targets $22. Weigh that against valuation and volatility. This is not personalized advice.
Is it too late to invest in NOV Inc.?
Not according to analysts: the median target ($22) is still +6% above the current price ($21) (most reliable on NOV: RBC Capital, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is NOV Inc. still worth investing in?
It depends on the gap between the price ($21) and its estimated value: analysts target $22 on median (+6%), with 33% buys (most reliable on NOV: RBC Capital, 100%). Cross-check with their real reliability on NOV and the cautions above. Information, not advice.
What's the main risk in buying NOV?
The consensus is not unanimous: of 9 ratings, 4 are neutral and 2 are sells.
→ Go deeper: the full NOV Inc. profile (consensus, analyst reliability, price target, performance).